Biotronik has announced the Food and Drug Administration (FDA) has approved the expansion of Biotronik’s ongoing ProMRI clinical trial. The new phase of the trial (Phase C) will study the company’s ProMRI technology in implantable cardioverter-defibrillator (ICD) devices. Biotronik is the only company in the world with an ICD that is approved for investigational use in a magnetic resonance imaging (MRI) scanner. The ongoing ProMRI study is the first step in making this standalone technology available in the United States.
If you enjoy this content, please share it with a colleague
The NDS Surgical Imaging (NDSsi) Dome S6c diagnostic display is a 6-megapixel (MP) LED widescreen model, and the latest addition to the S-series product family. It features 30-inch widescreen viewing, can be utilized as a single 6 MP or in dual 3 MP bezel-free format and provides both grayscale and color images. A native resolution of 3,280 by 2,048 makes it ideal for viewing a wide range of medical imaging modalities including computed radiography (CR), digital radiography (DR), magnetic resonance (MR), computed tomography (CT), positron emission tomography/computed tomography (PET/CT), ultrasound and 3-D volume rendering. Offering 800cd/m² high-bright LED-backlight technology and 1,000:1 contrast ratio, the Dome S6c delivers a new benchmark in optical clarity and image brilliance in varying ambient light environments.
As long as inexpensive statins, which lower cholesterol, are readily available and patients do not mind taking them, it does not make sense to do a heart comuted tomography (CT) scan to measure how much plaque has built up in a patient’s coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.
Data from several cutting-edge device clinical trials will be presented as late-breakers at the American College of Cardiology 63rd Annual Scientific Session & Expo (ACC.14), March 28-31.
UC Davis clinicians and physicists have recommended new strategies to make computed tomography (CT) safer, including adoption of a new metric for dose measurement, ways to manage exposure protocols that differ by CT brand and specific approaches to reduce exposure during needle biopsies.
If you enjoy this content, please share it with a colleague
Patient enrollment has been completed four months ahead of plan in the Phase III clinical trial EUCLID study for AstraZeneca's ticagrelor (Brilinta) tablets. Part of PARTHENON, AstraZeneca’s largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.
Digisonics will showcase its upcoming DigiView Release 3.8.4. for its Cardiovascular Information System (CVIS) at this year’s American College of Cardiology (ACC) annual scientific session in Washington, D.C., March 28-31.
Computed tomography (CT) imaging utilization has grown markedly across many clinical disciplines during the past decade, raising concerns about radiation overexposure.
If you enjoy this content, please share it with a colleague
Health Level announced the availability of Foundations Cardiology, a packaged solution that increases the speed and agility for cardiology centers by blending data from multiple applications and extending the role of the data warehouse to include real-time data analytics.
